QualityStocks would like to highlight
Avant Diagnostics, Inc. (
OTCQB: AVDX), a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In the company’s news,
Avant Diagnostics, Inc. (OTCQB: AVDX) recently made headlines when it announced plans to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). Under the terms of the previously announced Letter of Intent, Avant will issue 80 million shares of common stock to Amarantus upon execution of definitive merger agreements, which will represent roughly 45 percent of Avant’s post-merger common stock. An additional 10 million shares of common stock will be transferred upon achievement of predetermined sales milestones. According the company’s news release, the transaction is expected to be finalized in the second quarter of 2016, setting the stage for tremendous opportunities to progress Avant’s highly valuable diagnostic assets in the areas of oncology and neurology.
“After exploring numerous avenues for implementing Avant’s OvaDx® development and commercialization strategy, it is clear that combining Avant’s and Amarantus’ diagnostic assets and core competencies forms a platform that provides maximum value to our collective shareholders,” Gregg Linn, president and chief executive officer of Avant, stated in a news release.
The operational synergies between the two companies are expected to create significant opportunities for financial growth following completion of the proposed merger. Both Amarantus Diagnostics and Avant possess assets with the potential to provide early and actionable information to physicians and researchers by harnessing the power of biomarkers based in the immune system in disease areas that previously yielded results of limited value. Avant’s OvaDx® immuno-oncology diagnostic assay, for example, represents a significant improvement in the screening and diagnosis of ovarian cancer. Upon commercialization, it’s estimated that the market opportunity for OvaDX could be $50 million annually as a diagnostic test for ovarian cancer, and it could expand to over $2 billion if the test were to be approved as a generalized screening and/or monitoring tool.
“The collective diagnostic assets will create a truly unique opportunity to implement our respective missions of saving and enhancing lives through early detection of disease in oncology and neurology,” continued Linn. “The combined companies will enjoy additional benefits by creating a compelling platform to showcase the power diagnostics have to reduce costs and improve outcomes in the healthcare system.”
Amarantus Diagnostics’ development pipeline is expected to have similarly expansive market potential upon commercial approval. Its MSPrecise® neuroimmunology-based next-generation sequencing diagnostic assay for multiple sclerosis (MS), which is expected to greatly improve the diagnostic accuracy rate in MS while reducing costs for payers, will target a $200 million market, with the potential to address additional markets as a monitoring tool to measure the efficacy of drug treatment over time. Amarantus is also developing its innovative LymPro Test®, a neuroimmunology-based flow cytometry assay, for the early detection of Alzheimer’s disease.
Gerald E. Commissiong, president and chief executive officer of Amarantus, summarized the two companies’ optimism regarding the tremendous commercial potential of the merged company in a recent news release.
“We believe that combining these state-of-the-art technologies with a deep understanding of chronic disease rooted in immunology will produce a world-class diversified immuno-oncology and neuroimmunology focused diagnostics company able to deliver actionable information to physicians seeking to provide the most tailored treatment options for patients, while also assisting the research community in developing new medicines for these devastating disorders,” he said.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
